H3D Holistic Drug Discovery and Development Centre, University of Cape Town and H3D-Foundation
H3D’s core business is discovering novel medicines for diseases that predominantly affect African populations, such as malaria, tuberculosis, and antibiotic-resistant microbial diseases. A critical stakeholder in the South Africa Bioeconomy, H3D also focuses on the development of drug discovery technology and the training of young scientists.
SEE ALL PARTNER ORGANIZATIONS
The H3D Centre aims to:
- Discover and develop innovative, life-saving medicines for infectious diseases
- Build Africa-specific models to contribute to improving treatment outcomes in African patients
- Develop drug discovery platform technologies
- Train African scientists in drug discovery-related sciences
The H3D Foundation was established to complement the work of the H3D Drug Discovery and Development Centre, specifically in relation to capacity development that enables and unlocks the potential for sustainable drug discovery and development activities across Africa.
Partnership activities and how they address needs and challenges
H3D is the first and only centre of its kind on the African continent. It is a place where African scientists can utilize their scientific skills and education to improve the health of African patients and to educate the next generation of African pharmaceutical scientists.
H3D is uniquely positioned to seed the establishment of an innovative pharmaceutical industry in Africa. One of the key strengths of the Centre is its neutral positioning, which allows for strong partnerships with governments, philanthropies, industry, and academic partners, forming a bridge between academic and translational science.
H3D has four drug discovery portfolios (malaria, TB, AMR, and COVID-19) that are largely funded through research grants with a programmatic focus. H3D relies on an extensive international network of partners and collaborators to bring in relevant expertise and capacities to assist with sustaining the portfolio pipelines and delivering preclinical candidates. Product development and industry partners are particularly positioned to take any preclinical candidates emerging from the Centre through development.
"Our partnership with IFPMA members represents exactly the kind of commitment required to achieve the next breakthroughs and deliver new medicines to millions of people threatened by infectious diseases. These partnerships augment the support already provided by the South African Government’s Department of Science & Innovation and Technology Innovation Agency to build drug discovery and development capabilities on the African continent.”
Results and milestones
The H3D Centre has an infectious disease drug discovery portfolio with ~20 active projects and a global network with >30 active research partners. To date, the Centre has progressed 5 programs to selection phase and delivered 2 preclinical candidates.
* Celgene is a former member of this initiative.
- Infectious and Parasitic Disease
SGDs the partnership contributes to
- 3.3: Communicable diseases and NTDs
- 3.8: Achieve universal health coverage
- 3.C: Health workforce
King's College London
University of North Carolina (UNC) School of Public Health
H3D Holistic Drug Discovery and Development Centre
Swiss Tropical and Public Health Institute
Colorado State University
Infectious Disease Research Institute (IDRI)
University of Limpopo
University of Plymouth
Sapienza University of Rome
University of Venda
South African Medical Research Council
South African National Research Foundation
Texas A&M University
University of Cape Town
University of Pretoria
University of São Paulo
Newton Fund (UKRI)
South African Technology Innovation Agency
South African Department of Science and Technology
US National Institutes of Health (NIH)
Bill and Melinda Gates Foundation
Lead Molecular Design
Medicines for Malaria Venture (MMV)
BIO Ventures for Global Health (BVGH)
Global Alliance for TB Drug Development (TB Alliance)
- South Africa
Infectious and Parasitic Disease
- Drug-Resistant Infections (AMR)